Sanofi Reports meta-analysis Data for Mepolizumab in Prostate cancer

Sanofi today announced meta-analysis results for mepolizumab in patients with prostate cancer. The study demonstrated that mepolizumab demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of prostate cancer and support the continued development of mepolizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.